Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

In the June 2021 volume of the European Journal of Cancer, F. Duffaud et al. reported the efficacy and safety of regorafenib compared to placebo among 40 patients in the chondrosarcoma cohort of a non-comparative, randomised, double-blind, phase II clinical trial [1]. At median follow-up at 35.9 months, 13 (54%) compared to 5 (31%) patients did not progress at 12 weeks for patients treated with regorafenib versus placebo, respectively, and hence, did not meet its primary endpoint of 75% proportion of non-progressors at 12 weeks.

Lascia un commento